← FDA DRUG APPROVALS

FDA ANDA · ANDA209087

BUPIVACAINE HYDROCHLORIDE WITH DEXTROSE

Sponsor: B BRAUN MEDICAL

APPLICATION
ANDA209087
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-02
LATEST ACTION
2024-10-25
ROUTE
SUBARACHNOID, SPINAL
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

BUPIVACAINE HYDROCHLORIDEPrescription
BUPIVACAINE HYDROCHLORIDE 0.75% · INJECTABLE · SPINAL

Approval history

2024-10-25Labeling · Supplement 2 · standardAP
2019-04-02UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →